DPP-4 Inhibitor and Serum BNP Level of Diabetic Patients With Congestive Heart Failure
Heart Failure, Diabetes Mellitus
About this trial
This is an interventional treatment trial for Heart Failure
Eligibility Criteria
Outpatient arm
Inclusion Criteria:
- Type 2 diabetes patient with congestive heart failure under treatment with DPP-4 inhibitor (sitagliptin, vildagliptin, alogliptin, linagliptin, teneligliptin, anagliptin or saxagliptin) .
- High serum BNP (100-2000pg/ml).
- Patients who have given informed consent to participation in the study.
Exclusion Criteria:
- HbA1c over 9.0%.
- Patients who changed medication within 1 months before inclusion.
- Judged as ineligible by clinical investigators.
Hospitalization arm
Inclusion Criteria:
- Type 2 diabetes patient who were hospitalized for congestive heart failure.
- Patients who have given informed consent to participation in the study.
Exclusion Criteria:
- Patients on insulin therapy.
- Judged as ineligible by clinical investigators.
Sites / Locations
- Mitsui Memorial Hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Experimental
Outpatient arm
Hospitalization arm 1
Hospitalization arm 2
After baseline data collection, DPP-4 inhibitor will be suspended for one month and serum BNP will be measured. The DPP-4 inhibitor will be resumed and after another month, serum BNP will be measured again.
After hospitalization, medication for diabetes will be suspended. During the treatment for heart failure, drugs other than DPP-4 inhibitor will be resumed when required. After the stabilization of heart failure, DPP-4 inhibitor will be resumed (or administered if it was not prescribed before hospitalization) and serum BNP before and after the initiation of DPP-4 inhibitor will be measured.
After hospitalization, medication for diabetes may be suspended or continued. During the treatment for heart failure, drugs including DPP-4 inhibitor will be resumed when required. After the stabilization of heart failure, DPP-4 inhibitor will be suspended and serum BNP before and after the suspension of DPP-4 inhibitor will be measured.